Literature DB >> 12740345

Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats.

A Giacometti1, O Cirioni, R Ghiselli, F Mocchegiani, G D'Amato, M Simona Del Prete, F Orlando, W Kamysz, J Lukasiak, V Saba, G Scalise.   

Abstract

BACKGROUND: Postoperative morbidity in patients with obstructive jaundice remains high because of increased susceptibility to endotoxin and the inflammatory cascade. AIMS: An experimental study was designed to investigate the efficacy of protegrin peptide IB-367, an antimicrobial positively charged peptide, in neutralising Escherichia coli 0111:B4 lipopolysaccharide (LPS) in bile duct ligated rats.
METHODS: Adult male Wistar rats were injected intraperitoneally with 2 mg/kg E coli 0111:B4 LPS one week after sham operation or bile duct ligation (BDL). Six groups were studied: sham with placebo, sham with 120 mg/kg tazobactam-piperacillin (TZP), sham with 1 mg/kg IB-367, BDL with placebo, BDL with 120 mg/kg TZP, and BDL with 1 mg/kg IB-367.
RESULTS: Main outcome measures were: endotoxin and tumour necrosis factor alpha (TNF-alpha) concentrations in plasma, evidence of bacterial translocation in blood and peritoneum, and lethality. After LPS, TNF-alpha plasma levels were significantly higher in BDL rats compared with sham operated animals. IB-367 caused a significant reduction in plasma endotoxin and TNF-alpha concentrations compared with placebo and TZP treated groups. In contrast, both TZP and IB-367 significantly reduced bacterial growth compared with saline treatment. Finally, LPS induced 60% and 55% lethality in BDL placebo and TZP treated rats and no lethality in sham operated rats, while only IB-367 significantly reduced lethality to 10%.
CONCLUSIONS: By virtue of its dual antimicrobial and antiendotoxin properties, IB-367 could be an interesting compound to inhibit bacterial translocation and endotoxin release in obstructive jaundice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740345      PMCID: PMC1773671          DOI: 10.1136/gut.52.6.874

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

Review 1.  Bacterial translocation from the gastrointestinal tract.

Authors:  R D Berg
Journal:  J Med       Date:  1992

Review 2.  Treating patients with severe sepsis.

Authors:  A P Wheeler; G R Bernard
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

3.  Improved activity of a synthetic indolicidin analog.

Authors:  T J Falla; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  The abnormal lipid spectrum in malignant obstructive jaundice in relation to endotoxin sensitivity and the result of preoperative biliary drainage.

Authors:  N Kimmings; M E Sewnath; W M Mairuhu; A P Van Zanten; E A Rauws; S J Van Deventer; D J Gouma
Journal:  Surgery       Date:  2001-03       Impact factor: 3.982

5.  Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic Rat.

Authors:  D Harry; R Anand; S Holt; S Davies; R Marley; B Fernando; D Goodier; K Moore
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

6.  Kupffer cell blockade, tumour necrosis factor secretion and survival following endotoxin challenge in experimental biliary obstruction.

Authors:  J A Kennedy; H Lewis; W D Clements; S J Kirk; G Campbell; M I Halliday; B J Rowlands
Journal:  Br J Surg       Date:  1999-11       Impact factor: 6.939

7.  Biological properties of structurally related alpha-helical cationic antimicrobial peptides.

Authors:  M G Scott; H Yan; R E Hancock
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

8.  IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis.

Authors:  D A Mosca; M A Hurst; W So; B S Viajar; C A Fujii; T J Falla
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

9.  Conclusive evidence of endotoxaemia in biliary obstruction.

Authors:  W D Clements; P Erwin; M D McCaigue; I Halliday; G R Barclay; B J Rowlands
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

Review 10.  The pathogenesis of sepsis.

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

View more
  11 in total

1.  Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients.

Authors:  Yasuaki Takeyama; Yuko Uehara; Akira Anan; Daisuke Morihara; Keiji Yokoyama; Kazuhide Takata; Takashi Tanaka; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Med Mol Morphol       Date:  2017-06-28       Impact factor: 2.309

2.  LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.

Authors:  Oscar Cirioni; Andrea Giacometti; Roberto Ghiselli; Cristina Bergnach; Fiorenza Orlando; Carmela Silvestri; Federico Mocchegiani; Alberto Licci; Barbara Skerlavaj; Marco Rocchi; Vittorio Saba; Margherita Zanetti; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii.

Authors:  R López-Rojas; F Docobo-Pérez; M E Pachón-Ibáñez; B G de la Torre; M Fernández-Reyes; C March; J A Bengoechea; D Andreu; L Rivas; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

4.  Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats.

Authors:  Juntao Yang; Rongqian Wu; Mian Zhou; Ping Wang
Journal:  Peptides       Date:  2010-02-02       Impact factor: 3.750

Review 5.  Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.

Authors:  Haroon Mohammad; Shankar Thangamani; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Comparing selection on S. aureus between antimicrobial peptides and common antibiotics.

Authors:  Adam J Dobson; Joanne Purves; Wojciech Kamysz; Jens Rolff
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

7.  Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs.

Authors:  Susu M Zughaier; Pavel Svoboda; Jan Pohl
Journal:  Antibiotics (Basel)       Date:  2014-12

8.  Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse model.

Authors:  Chieh-Yu Pan; Jian-Chyi Chen; Te-Li Chen; Jen-Leih Wu; Cho-Fat Hui; Jyh-Yih Chen
Journal:  Mar Drugs       Date:  2015-04-14       Impact factor: 5.118

Review 9.  Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Authors:  Derry K Mercer; Deborah A O'Neil
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

10.  LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis.

Authors:  Gemma Odena; Jiegen Chen; Juan Jose Lozano; Jose Altamirano; Daniel Rodrigo-Torres; Silvia Affo; Oriol Morales-Ibanez; Hiroshi Matsushita; Jian Zou; Raluca Dumitru; Juan Caballeria; Pere Gines; Vicente Arroyo; Min You; Pierre-Emmanuel Rautou; Dominique Valla; Fulton Crews; Ekihiro Seki; Pau Sancho-Bru; Ramon Bataller
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.